New Enterprise Associates

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $24 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s track record of investing includes more than 260 portfolio company IPOs and more than 440 mergers and acquisitions. For more information, visit
Tyler Binney

Endeavour Vision

Endeavour Vision is a venture capital and growth equity firm founded in 2000, investing in growth-stage medtech, digital health and diagnostics companies in Europe and the US. Its investments are focused on transformative healthcare technologies that bring superior clinical benefits for patients and significant efficiencies to healthcare systems. Endeavour Vision’s international investment team, global network and extensive deal flow gives it a unique view on the sector, allowing investment opportunities in best-in-class or first-in-class technologies. The firm partners with companies in the early stages of commercializing game-changing technologies and actively supports them beyond capital with strategic and operational expertise. For more information, visit
Chris Geyen

Vensana Capital

Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Launched in 2019, Vensana manages $550M in capital and is actively investing in development and commercial stage companies across the medtech sector, including medical devices, diagnostics and data science, life science tools, digital health, and tech-enabled services. For more information, visit
Ray Baker


Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $6B under management, a diversified fund and over 200 exits to date, Canaan has invested in some of the world’s leading technology and healthcare companies over the past 33 years. Canaan’s focus areas include consumer tech, enterprise, fintech, frontier tech, biopharma, digital health and medtech. For more information, visit
Steve Augustine

Morgenthaler Ventures

Morgenthaler Ventures is a premier venture capital firm, dedicated to helping entrepreneurs build valuable companies for more than 40 years. The firm has $3 billion under management. Morgenthaler has invested in approximately 300 companies in the life science and information technology sectors.  Representative life science companies include: Ardian, Avidia, Catalyst Biosciences, Forsight Labs, Intergrated Vascular Systems, IPC – The Hospitalist Company, Medaphis, Morphotek, Moximed, OncoMed, Perclose, Principia, Promedior, Relievant, SetPoint Medical, Transcend, Twelve and Vapotherm.

Morgenthaler has offices in Menlo Park, CA, Boston, MA and Boulder, CO.  For more information, visit

Brian Donovan

Lightstone Ventures

Lightstone Ventures is a global venture capital firm investing in biotech and medtech companies pioneering big ideas poised to transform patient outcomes. Lightstone was founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary to bring their innovative therapeutics and technologies to the patients who need them most. Lightstone’s investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. The firm has offices in Boston, Mass., Menlo Park, Calif., Dublin, Ireland and Singapore and is currently investing out of Lightstone Ventures III, a $375M fund dedicated to life science start-ups. For more information, visit
Chris Gleason

Ally Bridge Group

Ally Bridge Group is a global healthcare investment management firm focused on high-impact life science innovation. The firm was founded in 2013 by Frank Yu, Chief Executive Officer and Chief Investment Officer, and manages assets from offices in New York and Hong Kong. Ally Bridge Group’s mission is to generate superior risk-adjusted returns for investors while seeking to address unmet medical needs. The firm aims to achieve this by blending deep scientific and clinical research with proven M&A and capital markets expertise. For more information, visit

Chris Gleason

Connect with Us

Follow us or reach out—we’d love to hear from you on our shared journey to relieve chronic low back pain.

Send us a note

Contact or follow us - We would love to hear from you